FDA leadership faces potential upheaval while new treatments advance for stroke prevention, muscular dystrophy, and weight management, alongside improved diagnostic tools for allergies and cardiovascular risk.

The White House has approved plans to fire FDA Commissioner Marty Makary, signaling a significant shift in pharmaceutical regulatory leadership under the Trump administration.

Factor XIa inhibitor asundexian demonstrated benefits beyond stroke prevention in the OCEANIC-STROKE trial, reducing both recurrent ischemic stroke risk and stroke severity when events occur.

NICE recommended givinostat for all types of Duchenne muscular dystrophy, potentially delaying disease progression by up to 5 years for approximately 530 patients in the UK.

A cruise ship hantavirus outbreak prompted WHO to develop emergency containment guidance, marking the first documented ship-borne transmission of the virus with outbreak management protocols under development.

Gastric sleeve endoscopy combined with weight loss showed significantly greater sustained weight reduction compared to lifestyle modification alone after GLP-1 therapy cessation.

Researchers developed an integrated genetic risk scoring system that improves prediction of eight cardiovascular conditions beyond current clinical tools, enhancing personalized risk assessment.

A novel blood test measuring basophil activation markers more accurately identifies sesame seed allergy in children compared to traditional skin prick and standard serum tests.

Early antiviral prophylaxis with oseltamivir administered to 70% of nursing home residents within 48 hours of outbreak onset significantly reduced hospitalizations, though implementation challenges exist in some countries.